Hong Kong · Vietnam · Myanmar · Philippines · Portugal · India
Healthcare for all.
Established in Hong Kong in 2011 as an API trading company, Saifen Drugs now distributes finished pharmaceuticals through affiliated entities across six territories — with a specialised sales force, a regulatory team and stock points in each of them.
- Established in Hong Kong
- 2011
- Territories of operation
- 6
- Products registered, submitted and ongoing
- 600+
Ho Chi Minh City — the group’s largest market since 2012
What we do
Four ways a product reaches its market
Registration, distribution and promotion are run by our own people in each country of operation rather than subcontracted — which is what makes an on-time launch something we can commit to.
Sales & marketing
A specialised sales force in each country, with a dedicated marketing support team behind it.
Distribution
Sound infrastructure and reach into every part of each country, with multiple stock points.
Product registration
A dedicated regulatory team in each country of operation, for on-time product launch.
Exclusive projects
A direct-to-customer application in development, delivering medicines to the patient’s home or workplace.
Our presence
Six territories, one operating company in each
Each market is run by a registered local entity with its own sales force, its own regulatory team and its own stock points — not by an agent acting on the group’s behalf.
Hong Kong
Central
Saifen Drugs (Hong Kong) Limited
Registered office and group holding company, since 2011
Vietnam
Ho Chi Minh City
An Phat Co., Ltd.
300+ products registered · US$16.5 M — the largest market
Myanmar
Yangon
Aveda Limited
200+ products registered · US$3.4 M
Philippines
Metro Manila
Saifen Drugs Philippines Inc.
100+ products registered · US$1.5 M
Portugal
Lisbon
Saifen Drugs Portugal, Unipessoal Lda
European sourcing and the group’s EU footing
India
Ahmedabad
Saifen Drugs India Private Limited
Sourcing, development and manufacturing
2011
Hong Kong
Saifen Drugs (Hong Kong) Limited
2012
Vietnam
An Phat Co., Ltd.
2016
Myanmar
Aveda Limited
2018
Philippines
Saifen Drugs Philippines Inc.
2023
Portugal
Saifen Drugs Portugal, Unipessoal Lda
2023
India
Saifen Drugs India Private Limited
The portfolio
What the group actually moves
Three commercial markets, a portfolio weighted toward the therapy areas where a first generic is worth launching, and registrations held in the group’s own name.
Vietnam
US$16.5 M
300+ Registrations
Myanmar
US$3.4 M
200+ Registrations
Philippines
US$1.5 M
100+ Registrations
Portfolio by therapy area
- Anti-infectives
- 32.2%
- Cardiovascular
- 26.7%
- Oncology
- 22.8%
- Anti-diabetics and others
- 18.3%
Registrations include products registered, submitted and in progress.
Sold under the group’s own labels
The group does not only move other companies’ boxes. It builds and markets its own, and these eight are sold under Aveda — its label in Myanmar.
Zaviclovir
Aciclovir 5% w/w
Cream
Clomazol
Clotrimazole 1% w/w
Cream
Fenazol
Miconazole Nitrate
Cream
Eczederm
Clobetasol 0.05% w/w
Ointment
MNO-each
Clotrimazole 100 mg
Vaginal tablets
Avelergy Plus
Fexofenadine Hydrochloride 60 mg/5 ml
Oral suspension
Rhinizill
Mometasone Furoate 50 mcg
Nasal spray
Mucotame
Salbutamol 2 mg/5 ml
Oral solution
Purpose
What the group is for
Guiding principle
Service before self.
- Mission
- To feature among the top three distribution companies in each country we operate in.
- Vision
- To provide affordable medication by launching the first generic in the market.
The seven, and what each one means here
One set of expectations across six territories and six operating companies.
Customer service
The customer’s need is where every review starts.
Innovation
First generics, new chemical entities, new delivery systems.
Honesty
Claims a health authority can hold us to.
Performance
On-time launches, and the least variation after them.
Intelligence
Products shortlisted on research rather than on hope.
Teamwork
Regulatory, sales and distribution as one team per country.
Leadership
The top three in every market, or the job is not finished.
Vision 2036
The next ten years, already dated
Three of them are here. The full roadmap runs in three acts, from a land acquisition at Dholera in 2026 to a group turnover of INR 3,000 crore in December 2036.
- 2030
- Facility Vietnam’s largest pharmaceutical finished-product factory
- 2034
- Market entry A foothold in the United States market
- 2035
- Facility India’s biggest biotech factory, operational at Dholera SIR
Partners
Forty-three manufacturers, two supply bases
The group sources from established European and Indian manufacturers, and holds the registrations in its own name in each market it serves.
Also supplying Pharma Srl · Madras Pharma · Globela Pharma · Zeiss Pharma · Karnataka Antibiotics · RA Chem Pharma · Softgel Healthcare.
From the Managing Director
“A company should focus on the customer’s need, dream big, and develop its people. Thinking inside out and focusing on contribution provides value for money to the customer and creates wealth for stakeholders.”
Get in touch
We care for your welfare